APA746Hu03 100μg
Active Fibroblast Growth Factor 23 (FGF23)
Organism Species: Homo sapiens (Human)

FOR RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

1st Edition (Apr, 2016)

[ PROPERTIES ]
Source: Prokaryotic expression.
Host: E. coli
Residues: Asp79~Arg160
Tags: N-terminal His-tag
Purity: >95%
Endotoxin Level: <1.0EU per 1μg (determined by the LAL method).
Buffer Formulation: 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl and 5% trehalose.
Applications: Cell culture; Activity Assays.
(May be suitable for use in other assays to be determined by the end user.)
Predicted isoelectric point: 7.9
Predicted Molecular Mass: 10.8kDa
Accurate Molecular Mass: 11kDa as determined by SDS-PAGE reducing conditions.

[ USAGE ]
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

[ STORAGE AND STABILITY ]
Storage: Avoid repeated freeze/thaw cycles.
Store at 2-8°C for one month.
Aliquot and store at -80°C for 12 months.
**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

**SEQUENCE**

DA GFVITGVMS RRylcmdfrg
NIFGSHYFDp ENCRFQHQTl ENGYDVYhsp QyHflvslgr AKRAFLPGMN PPPYSQFLSR

**ACTIVITY**

Fibroblast growth factor 23 or FGF23 is a member of the fibroblast growth factor (FGF) family which is responsible for phosphate and vitamin D metabolism. The main function of FGF23 seems to be regulation of phosphate concentration in plasma. FGF23 decreases the reabsorption and increases excretion of phosphate and suppress 1-alpha-hydroxylase, reducing its ability to activate vitamin D and subsequently impairing calcium absorption. Besides, Fibroblast Growth Factor Receptor 2 (FGFR2) has been identified as an interactor of FGF23, thus a binding ELISA assay was conducted to detect the interaction of recombinant human FGF23 and recombinant human FGFR2. Briefly, FGF23 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100μL were then transferred to FGFR2-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-FGF23 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50μL stop solution to the wells and read at 450nm immediately. The binding activity of FGF23 and FGFR2 was shown in Figure 1, and this effect was in a dose dependent manner.
Figure 1. The binding activity of FGF23 with FGFR2.

[ IDENTIFICATION ]

Figure 2. SDS-PAGE

Sample: Active recombinant FGF23, Human
Figure 3. Western Blot

Sample: Recombinant FGF23, Human;
Antibody: Rabbit Anti-Human FGF23 Ab (PAA746Hu03)

[ IMPORTANT NOTE ]

The kit is designed for in vitro and research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.